Schering Rebetron Hepatitis C Therapy Five Year Phase IV Data Requested

Schering-Plough will submit five-year follow-up data from its four pivotal trials of Rebetron as part of its Phase IV commitments to FDA. The combination therapy of Schering's Intron A (interferon alfa-2b) injection and Rebetol (Schering/ICN's ribavirin) for hepatitis C was approved June 3.